Thermo Fisher Scientific IL-28A Polyclonal Antibody, PeproTech

Applications and Tested Dilution

Product Specifications

Product Specific Information

Amino Acid Sequence of Recombinant Protein:
PVARLHGALP DARGCHIAQF KSLSPQELQA FKRAKDALEE SLLLKDCRCH SRLFPRTWDL RQLQVRERPM ALEAELALTL KVLEATADTD PALVDVLDQP LHTLHHILSQ FRACIQPQPT AGPRTRGRLH HWLYRLQEAP KKESPGCLEA SVTFNLFRLL TRDLNCVASG DLCV.

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human IFN-lambda2. Anti-Human IFN-lambda2-specific antibody was purified by affinity chromatography employing an immobilized Human IFN-lambda2 matrix.

Sandwich ELISA:
To detect Human IFN-lambda2 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.5–2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IFN-lambda2 (500-P247Bt) as a detection antibody, allows the detection of at least 0.2–0.4 ng/well of Recombinant Human IFN-lambda2.

Western Blot:
To detect Human IFN-lambda2 by Western Blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. When used with compatible secondary reagents, the detection limit for Recombinant Human IFN-lambda2 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Target Information

IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), also known as type III Interferons.

The IFN lambdas signal through a heterodimeric receptor composed of IL-10R2 (shared with other IL-10 family members) and IFN lambda R1 (IL-28R alpha), which is unique to this family. Signaling occurs through the Jak/STAT pathway, similar to type I IFNs (alpha/beta), activating many of the same genes despite low sequence homology. Both IFN families exhibit antiviral activity by inducing antiviral proteins and upregulating MHC class I expression. They also show antiproliferative and antitumor effects, suggesting potential use as alternatives to IFN alpha therapies.

Unlike type I IFNs, IFN lambda responses are limited to dendritic and certain tumor cells due to restricted expression of IFN lambda R1. IFN lambda stimulation can also drive dendritic cells to produce CD4+CD25+FoxP3+ regulatory T cells, indicating a possible immunoregulatory role.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.